Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
Objective: Pegylated liposomal doxorubicin (PLD) is a stealth liposomal form of doxorubicin that has been approved for the treatment of patients with relapsed ovarian cancer. Previous studies have shown a response rate of about 25% in patients who had treatment failure with prior platinum- and/or pa...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2004-09-01
|
| Edice: | Taiwanese Journal of Obstetrics & Gynecology |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S1028455909600711 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|